The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Participants will be followed for up to 5 years. During routine clinic visits, researchers will collect their TCM information (such as tongue images and pulse readings) and store small samples of their blood, stool, and tongue coating for future research.
Pathologically or histologically confirmed non-small cell lung cancer (NSCLC)
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Presence of epidermal growth factor receptor (EGFR) mutation confirmed by genetic testing
Unable to comply with baseline assessments
Pregnant or breastfeeding women
Presence of other uncontrolled malignancies
Presence of severe brain diseases or psychiatric disorders that affect the patient's ability to communicate or provide informed consent
Guangzhou University of Traditional Chinese Medicine
Lead sponsor
Beijing Chest Hospital
Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborator
Sichuan Cancer Hospital and Research Institute
Collaborator
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Collaborator
Affiliated Hospital of Xinxiang Medical University, Henan province
Collaborator